Nuvation Bio Files Definitive Proxy Statement
Ticker: NUVB · Form: DEF 14A · Filed: Apr 8, 2025 · CIK: 1811063
Sentiment: neutral
Topics: proxy-statement, annual-meeting, governance
TL;DR
Nuvation Bio's proxy statement is in, annual meeting May 21. Vote your shares!
AI Summary
Nuvation Bio Inc. filed its definitive proxy statement (DEF 14A) on April 8, 2025, for its annual meeting on May 21, 2025. The company, formerly known as Panacea Acquisition Corp. until April 30, 2020, is seeking shareholder approval for matters related to its corporate governance and operations. The filing indicates no fee was required for this submission.
Why It Matters
This filing outlines the key proposals and information shareholders will vote on, impacting the company's future direction and governance.
Risk Assessment
Risk Level: low — This is a routine proxy filing for an annual meeting, not indicating immediate financial distress or significant new risks.
Key Numbers
- 001-39351 — SEC File Number (Identifies the company's registration with the SEC.)
Key Players & Entities
- Nuvation Bio Inc. (company) — Registrant
- Panacea Acquisition Corp. (company) — Former company name
- 0001811063 (company) — Central Index Key
- 20250408 (date) — Filing date
- 20250521 (date) — Meeting date
FAQ
What is the purpose of this DEF 14A filing?
The DEF 14A filing is a definitive proxy statement filed by Nuvation Bio Inc. for its annual shareholder meeting.
When is the Nuvation Bio Inc. annual meeting scheduled?
The annual meeting is scheduled for May 21, 2025.
What was Nuvation Bio Inc.'s former name?
Nuvation Bio Inc.'s former name was Panacea Acquisition Corp., with a name change effective April 30, 2020.
What is the company's primary industry classification?
Nuvation Bio Inc. is classified under Pharmaceutical Preparations [2834].
Was there a filing fee associated with this proxy statement?
No fee was required for this filing, as indicated by the 'No fee required' checkbox being selected.
Filing Details
This Form DEF 14A (Form DEF 14A) was filed with the SEC on April 8, 2025 regarding Nuvation Bio Inc. (NUVB).